Special communication

Should medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes*

This study was supported by grants HS 06336 and 08397 from the Agency for Health Care Policy and Research, and contract no. K3-0546.0 from the Office of Technology Assessment, Congress of the United States. The conclusions are solely those of the authors and do not represent the views of the Office of Technology Assessment, the Technology Assessment Board, or the United States Congress.

Michael J. Barry, M.D., Medical Practices Evaluation Center, Massachusetts General Hospital, Boston, MA 02114.